CA3191582A1 - Ribitol treatment - Google Patents
Ribitol treatmentInfo
- Publication number
- CA3191582A1 CA3191582A1 CA3191582A CA3191582A CA3191582A1 CA 3191582 A1 CA3191582 A1 CA 3191582A1 CA 3191582 A CA3191582 A CA 3191582A CA 3191582 A CA3191582 A CA 3191582A CA 3191582 A1 CA3191582 A1 CA 3191582A1
- Authority
- CA
- Canada
- Prior art keywords
- day
- ribitol
- dose
- comprises administering
- bid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Saccharide Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063076761P | 2020-09-10 | 2020-09-10 | |
| US63/076,761 | 2020-09-10 | ||
| PCT/US2021/049677 WO2022056137A1 (en) | 2020-09-10 | 2021-09-09 | Ribitol treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3191582A1 true CA3191582A1 (en) | 2022-03-17 |
Family
ID=80629815
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3191582A Pending CA3191582A1 (en) | 2020-09-10 | 2021-09-09 | Ribitol treatment |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230364118A1 (https=) |
| EP (1) | EP4210708A4 (https=) |
| JP (1) | JP2023544249A (https=) |
| KR (1) | KR20230069941A (https=) |
| CN (1) | CN117355310A (https=) |
| AU (1) | AU2021338706A1 (https=) |
| CA (1) | CA3191582A1 (https=) |
| IL (1) | IL301088A (https=) |
| MX (1) | MX2023001881A (https=) |
| WO (1) | WO2022056137A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10434113B2 (en) | 2016-12-16 | 2019-10-08 | The Charlotte Mecklenburg Hospital Authority | Compositions and methods for treating muscular dystrophy and other disorders |
| AU2020283556A1 (en) | 2019-05-28 | 2022-01-06 | The Charlotte-Mecklenburg Hospital Authority D/B/A Atrium Health | Compositions and methods of making ribitol |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10245235B2 (en) * | 2016-12-16 | 2019-04-02 | The Charlotte-Mecklenburg Hospital Authority | Compositions and methods for treating muscular dystrophy and other disorders |
| US20200061092A1 (en) * | 2018-08-24 | 2020-02-27 | The Charlotte Mecklenburg Hospital Authority D/B/A Atrium Health | Methods and compositions for treating disorders associated with muscle weakness |
-
2021
- 2021-09-09 AU AU2021338706A patent/AU2021338706A1/en active Pending
- 2021-09-09 IL IL301088A patent/IL301088A/en unknown
- 2021-09-09 WO PCT/US2021/049677 patent/WO2022056137A1/en not_active Ceased
- 2021-09-09 MX MX2023001881A patent/MX2023001881A/es unknown
- 2021-09-09 CN CN202180073484.0A patent/CN117355310A/zh active Pending
- 2021-09-09 US US18/044,747 patent/US20230364118A1/en active Pending
- 2021-09-09 CA CA3191582A patent/CA3191582A1/en active Pending
- 2021-09-09 JP JP2023515723A patent/JP2023544249A/ja active Pending
- 2021-09-09 KR KR1020237010497A patent/KR20230069941A/ko active Pending
- 2021-09-09 EP EP21867600.5A patent/EP4210708A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021338706A1 (en) | 2023-05-25 |
| CN117355310A (zh) | 2024-01-05 |
| EP4210708A1 (en) | 2023-07-19 |
| EP4210708A4 (en) | 2024-10-23 |
| WO2022056137A1 (en) | 2022-03-17 |
| IL301088A (en) | 2023-05-01 |
| JP2023544249A (ja) | 2023-10-23 |
| MX2023001881A (es) | 2023-04-03 |
| US20230364118A1 (en) | 2023-11-16 |
| KR20230069941A (ko) | 2023-05-19 |
| WO2022056137A9 (en) | 2022-04-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12427161B2 (en) | Methods for treating and pharmaceutical compositions | |
| US20240398729A1 (en) | Methods and Compositions for the Treatment of Cytoplasmic Glycogen Storage Disorders | |
| JP2026035578A (ja) | ファブリー病の治療用投薬レジメン | |
| JP6612370B2 (ja) | ポンペ病の処置のための投与計画 | |
| KR20220127832A (ko) | 근위축성 측삭 경화증 및 관련 장애의 치료 | |
| AU2010262970A1 (en) | Compositions and methods for treating amyotrophic lateral sclerosis | |
| WO2018222655A1 (en) | Methods of treating fabry patients having renal impairment | |
| TW200808324A (en) | Method for shortening hospital stay in patients with congestive heart failure and acute fluid overload | |
| RS63742B1 (sr) | Metode unapređenja i/ili stabilizacije srčanih funkcija kod pacijenata sa fabrijevom bolešću | |
| US10751298B2 (en) | Compositions and methods for treating muscular dystrophy and other disorders | |
| US20230364118A1 (en) | Ribitol treatment | |
| WO2012154779A1 (en) | Combinations of oxybutynin and salivary stimulants for the treatment of overactive bladder | |
| Katz et al. | The antiobsessional effects of clomipramine do not require concomitant affective disorder | |
| WO2012154892A1 (en) | Combinations of propiverine and salivary stimulants for the treatment of overactive bladder | |
| RS65230B1 (sr) | Migalastat za lečenje pacijenata koji boluju od fabrijeve bolesti sa oštećenjem bubrega | |
| WO2012154893A1 (en) | Combinations of trospium and salivary stimulants for the treatment of overactive bladder | |
| Vitse et al. | First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple oral doses of SAR247799, a selective G-protein-biased Sphingosine-1 phosphate receptor-1 agonist for endothelial protection. | |
| Kassem et al. | A Review of Patisiran (ONPATTROÒ) for the Treatment of Polyneuropathy in People with Hereditary Transthyretin Amyloidosis | |
| WO2026013261A1 (en) | Nizubaglustat for use in the treatment of lysosomal storage disorders | |
| WO2024054412A1 (en) | Methods and compositions for treating amyotrophic lateral sclerosis | |
| WO2012154778A1 (en) | Combinations of imidafenacin and salivary stimulants for the treatment of overactive bladder | |
| WO2012154775A1 (en) | Combinations of darifenacin and salivary stimulants for the treatment of overactive bladder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240805 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240805 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250901 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250901 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250909 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250909 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250909 |